The disparity in the efficacy of PD-1 or PD-L1 blockade antibodies in different types of cancer underscores the need to develop novel strategies of immunotherapy that may overcome the limitations of existing immunotherapeutic agents. The gene discussed is PDCD1; the disease is cancer.